BN three-lens brief
Evidence-based stock research on BN. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 2% of its 52-week range — deep in the lower band.
- Trading at 2% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- RSI at 26 — technically oversold.
- Underperforming SPY by 12.6pp over 30 days.
- P/E of 72 — priced for high growth; little margin of safety.
BN closed at $38.05 (-1.22%) as of 2026-09-11. Market cap: $84.94B. P/E (trailing) 71.8. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $54.40 — 43% above current (10 analysts).. Concerns: trading at 2% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $1.61B, free cash flow -$1.98B.
Why three lenses on BN, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BNacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BN" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BN brief"></iframe>